NTHI News

NeOnc Technologies Holdings (NASDAQ:NTHI) delivered a deeply human clinical update that brings its investigational brain-cancer technology, expanding Abu Dhabi presence and high-profile banking appointment into sharper focus. The company reported that a critically ill three-year-old boy with an aggressive brain tumor is breathing independently without ventilator support and beginning to move his legs after receiving investigational intranasal NEO100 through NeOnc’s Compassionate Care program. The treatment is being administered outside the company’s pediatric clinical trial, following coordination with the child’s physicians and the Department of Health – Abu Dhabi. While a single compassionate-use case cannot establish that NEO100 caused the reported improvement, the decision to make an investigational treatment available to a critically ill child underscores the importance of the technology to NeOnc’s development strategy and raises the stakes for the company to demonstrate its potential through rigorous clinical research.

The following developments are worth watching, with Dermata Therapeutics (NASDAQ:DRMA), Verastem (NASDAQ:VSTM), NeOnc Technologies Holdings (NASDAQ:NTHI), Netcapital (NASDAQ:NCPL), Iambic Therapeutics (NASDAQ:IAM) and Estrella Immunopharma (NASDAQ:ESLA) advancing distinct strategies.

The right appointment can do far more than fill a board seat. It can elevate a company’s public profile, open doors to strategic partnerships, influence commercial direction and reshape how investors view its growth potential. $NTHI, $PZZA, $TSLA,  $SPCX, $UMAC

NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its boardroom at a pivotal moment in its brain-cancer drug development strategy, appointing Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank (FAB), to its Board of Directors.

The market is serving up a powerful mix of movers, including Alaunos Therapeutics (NASDAQ:TCRT) completed a major acquisition backed by a $350 million private placement, while NeOnc Technologies Holdings (NASDAQ:NTHI) is preparing for an important FDA discussion. Verastem Oncology (NASDAQ:VSTM) reported fresh cancer-drug results alongside a major financing and leadership transition, and Liquidia (NASDAQ:LQDA) resolved a prolonged legal battle over its pulmonary-hypertension treatment. Bending Spoons (NASDAQ:BSP) is attracting another major investment from Berkshire Hathaway.

NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its leadership as it advances clinical development of therapies targeting some of the most challenging cancers to treat. The clinical-stage biopharmaceutical company appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors, effective October 9, 2026. With more than three decades of international banking and executive leadership experience, Alabedin brings financial governance and global business expertise as NeOnc pursues clinical-development opportunities in Abu Dhabi and advances its brain cancer drug pipeline.